慢性阻塞性肺疾病患者雾化吸入复方异丙托溴铵及布地奈德的临床疗效分析  

Clinical Analysis of Chronic Obstructive Pulmonary Disease Patients With Inhalation of Ipratropium Bromide and Budesonide

作　　者：李业梅[1] 俞小卫[1] 左一俊[1] 

机构地区：[1]南京医科大学附属常州第二人民医院呼吸科,江苏常州213003

出　　处：《中国继续医学教育》2016年第34期146-147,共2页China Continuing Medical Education

摘　　要：目的探讨雾化吸入复方异丙托溴铵联合布地奈德治疗慢性阻塞性肺疾病（Chronic Obstructive Pulmonary Disease,COPD）患者的临床疗效。方法选择2014年6月~2016年1月我院接受诊治的COPD急性加重期的患者296例,随机分为治疗组和对照组,各有148例。两组患者均给予对症基础治疗,治疗组应用雾化吸入复方异丙托溴铵及布地奈德疗法,对照组使用庆大霉素和α-糜蛋白治疗。观察两组患者的症状缓解时间和不良反应。结果治疗组治疗后的症状缓解时间少于对照组,血氧饱和度比对照组明显改善,不良反应（3.38%）少于对照组（16.22%）,差异有统计学意义（P〈0.05）。结论雾化吸入复方异丙托溴铵联合布地奈德能有效缓解慢性阻塞性肺疾病患者的病情状态,减少不良反应率。Objective To investigate the inhalation of combivent combined with budesonide in the treatment of chronic obstructive pulmonary disease（Chronic Obstructive Pulmonary Disease,COPD） in patients with clinical efficacy. Methods From June 2014 to January 2016,296 COPD cases with acute exacerbation,who was diagnosis and treatment in our hospital,were randomly divided into treatment group and control group,each group had 148 cases. Two groups of patients were given symptomatic therapy,the treatment group used nebulized ipratropium bromide and budesonide therapy,the control group used gentamicin and alpha chymotrypsin treatment. The symptom relief time and adverse reaction of the two groups were observed. Results In the treatment group,the remission time of symptoms was less than that of the control group,blood oxygen saturation was significantly improved than that of the control group,the adverse reactions was（3.38%） less than the control group（16.22%）,the difference was statistically significant（P〈0.05）. Conclusion Inhalation of ipratropium bromide combined with budesonide can effectively relieve patients with chronic obstructive pulmonary disease condition,reduce the rate of adverse reactions.

关 键 词：慢性阻塞性肺疾病 急性加重期 复方异丙托溴铵 布地奈德 雾化吸入 

分 类 号：R974[医药卫生—药品]